• 1. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 2. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 3. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 4. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 5. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147

Introduction to 5-Bromo-2-chloropyrimidine-4-carboxylic acid (CAS No. 933739-55-0)

5-Bromo-2-chloropyrimidine-4-carboxylic acid, identified by the Chemical Abstracts Service Number (CAS No.) 933739-55-0, is a significant intermediate in the realm of pharmaceutical and agrochemical research. This compound belongs to the pyrimidine family, a heterocyclic aromatic organic compound that serves as a fundamental building block in medicinal chemistry. The presence of both bromo and chloro substituents on the pyrimidine ring enhances its reactivity, making it a valuable precursor for synthesizing various biologically active molecules.

The structural features of 5-Bromo-2-chloropyrimidine-4-carboxylic acid contribute to its versatility in chemical transformations. The carboxylic acid moiety at the 4-position allows for further functionalization through esterification, amidation, or carboxylation reactions, while the bromo and chloro groups are susceptible to nucleophilic substitution, leading to the introduction of diverse functional groups. These properties have made this compound a focal point in synthetic organic chemistry and drug discovery efforts.

In recent years, 5-Bromo-2-chloropyrimidine-4-carboxylic acid has garnered attention in the development of novel therapeutic agents. Its structural motif is closely related to several known pharmacophores, particularly those targeting metabolic pathways and signal transduction cascades. For instance, pyrimidine derivatives have been extensively studied for their potential in treating diseases such as cancer, infectious disorders, and inflammatory conditions. The halogenated pyrimidines, including 5-Bromo-2-chloropyrimidine-4-carboxylic acid, exhibit promising activities as kinase inhibitors, antiviral agents, and antimicrobial compounds.

One of the most compelling applications of 5-Bromo-2-chloropyrimidine-4-carboxylic acid is in the synthesis of small-molecule inhibitors targeting protein kinases, which play a crucial role in cell proliferation and survival. Research has demonstrated that halogenated pyrimidines can disrupt kinase activity by binding to specific pockets on the enzyme's active site. For example, derivatives of 5-Bromo-2-chloropyrimidine-4-carboxylic acid have been investigated for their ability to inhibit tyrosine kinases and serine/threonine kinases, which are overexpressed in various cancers. These findings highlight the compound's potential as a lead molecule in oncology research.

Moreover, the carboxylic acid group in 5-Bromo-2-chloropyrimidine-4-carboxylic acid provides an opportunity for further derivatization to enhance solubility and bioavailability. By converting the carboxylate group into esters or amides, researchers can modulate the pharmacokinetic properties of derived compounds. This approach has been employed in several drug development programs to improve oral bioavailability and tissue distribution. Such modifications are critical for translating promising preclinical candidates into viable therapeutic agents.

The synthesis of 5-Bromo-2-chloropyrimidine-4-carboxylic acid typically involves multi-step organic reactions starting from commercially available pyrimidine precursors. The introduction of bromo and chloro substituents can be achieved through halogenation reactions using reagents such as N-bromosuccinimide (NBS) or phosphorus oxychloride (POCl?). The subsequent carboxylation at the 4-position is often performed using strong acidic conditions or metal-catalyzed reactions. These synthetic strategies have been optimized to ensure high yield and purity, making 5-Bromo-2-chloropyrimidine-4-carboxylic acid readily accessible for further applications.

Recent advances in computational chemistry have further accelerated the discovery process involving 5-Bromo-2-chloropyrimidine-4-carboxylic acid. Molecular modeling techniques allow researchers to predict binding affinities and optimize lead structures before experimental synthesis. This integration of computational methods with traditional organic synthesis has significantly reduced the time required to develop novel compounds. Additionally, high-throughput screening technologies have enabled rapid testing of large libraries of derivatives, facilitating the identification of potent bioactive molecules.

In conclusion, 5-Bromo-2-chloropyrimidine-4-carboxylic acid (CAS No. 933739-55-0) represents a versatile intermediate with broad applications in pharmaceutical research. Its unique structural features make it an invaluable tool for synthesizing biologically active compounds targeting various diseases. As research continues to uncover new therapeutic opportunities, compounds like 5-Bromo-2-chloropyrimidine-4-carboxylic acid will undoubtedly play a pivotal role in shaping the future of drug development.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)